Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis

M. Asefi, A. Vaisi-Raygani, F. Bahrehmand, A. Kiani, Z. Rahimi, H. Nomani, A. Ebrahimi, H. Tavilani, Tayebeh Pourmotabbed

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background Paraoxonase 1 (PON1) is a serum high-density lipoprotein-bound enzyme with antioxidant function. It hydrolyses lipid peroxides, protecting low-density lipoproteins from oxidative modifications. Patients with psoriasis are at greater risk of oxidative stress, which is associated with abnormal plasma lipid metabolism. Objectives In this study, association of the PON1 55 M allele with serum arylesterase (ARE) activity, malondialdehyde (MDA), lipid profiles and psoriasis was investigated. Methods The present case-control study consisted of 100 patients with psoriasis with and without cardiovascular diseases (mean age 35·3 years) and 100 sex- and age-matched unrelated healthy controls (mean age 35·7 years) from the population of western Iran. The PON1 55 Met>Leu polymorphism was detected by polymerase chain reaction-restriction fragment length polymorphism. Serum ARE activity, MDA, and lipid and apolipoprotein levels were determined spectrophotometrically, by high-performance liquid chromatography and by enzyme assay, respectively. Results The presence of the PON1 55 M allele was found to be associated with psoriasis (odds ratio = 1·96, P = 0·017). The patients with psoriasis with the PON1 M (M/L + M/M) allele had higher MDA levels (4·12 ± 0·88 vs. 2·24 ± 0·55 μmol L -1, P < 0·001), apolipoprotein B (APOB)/APOA1 ratio (0·91 ± 0·66 vs. 0·66 ± 0·35, P = 0·004), APOB (111 ± 38·7 vs. 88·3 ± 22·5 mg mL-1, P = 0·001) and lipoprotein(a) [LP(a)] (21·9 ± 18·4 vs. 15·8 ± 16·6 mg mL-1, P = 0·034), but lower ARE activity (39·6 ± 11 vs. 45·9 ± 11·8 U mL-1, P = 0·031) than the control subjects. ARE activity showed a significant positive correlation with APOA1 and a negative correlation with MDA concentration in patients with psoriasis. Conclusions The PON1 55 M allele is a risk factor for psoriasis. Carriers of this allele have high levels of MDA, APOB and LP(a), a high APOB/APOA1 ratio and low ARE activity. These results indicate that oxidative stress, impairment of the antioxidant system and abnormal lipid metabolism may play a role in the pathogenesis and progression of psoriasis and its related complications. These data suggest that patients with psoriasis are more susceptible to vascular diseases.

Original languageEnglish (US)
Pages (from-to)1279-1286
Number of pages8
JournalBritish Journal of Dermatology
Volume167
Issue number6
DOIs
StatePublished - Dec 1 2012

Fingerprint

Aryldialkylphosphatase
Psoriasis
Lipids
Malondialdehyde
Apolipoproteins B
Alleles
Lipoprotein(a)
Lipid Metabolism
Oxidative Stress
Antioxidants
Serum
Apolipoproteins
Lipid Peroxides
Enzyme Assays
HDL Lipoproteins
Iran
Vascular Diseases
LDL Lipoproteins
Restriction Fragment Length Polymorphisms
Case-Control Studies

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Asefi, M., Vaisi-Raygani, A., Bahrehmand, F., Kiani, A., Rahimi, Z., Nomani, H., ... Pourmotabbed, T. (2012). Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis. British Journal of Dermatology, 167(6), 1279-1286. https://doi.org/10.1111/j.1365-2133.2012.11170.x

Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis. / Asefi, M.; Vaisi-Raygani, A.; Bahrehmand, F.; Kiani, A.; Rahimi, Z.; Nomani, H.; Ebrahimi, A.; Tavilani, H.; Pourmotabbed, Tayebeh.

In: British Journal of Dermatology, Vol. 167, No. 6, 01.12.2012, p. 1279-1286.

Research output: Contribution to journalArticle

Asefi, M, Vaisi-Raygani, A, Bahrehmand, F, Kiani, A, Rahimi, Z, Nomani, H, Ebrahimi, A, Tavilani, H & Pourmotabbed, T 2012, 'Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis', British Journal of Dermatology, vol. 167, no. 6, pp. 1279-1286. https://doi.org/10.1111/j.1365-2133.2012.11170.x
Asefi M, Vaisi-Raygani A, Bahrehmand F, Kiani A, Rahimi Z, Nomani H et al. Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis. British Journal of Dermatology. 2012 Dec 1;167(6):1279-1286. https://doi.org/10.1111/j.1365-2133.2012.11170.x
Asefi, M. ; Vaisi-Raygani, A. ; Bahrehmand, F. ; Kiani, A. ; Rahimi, Z. ; Nomani, H. ; Ebrahimi, A. ; Tavilani, H. ; Pourmotabbed, Tayebeh. / Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis. In: British Journal of Dermatology. 2012 ; Vol. 167, No. 6. pp. 1279-1286.
@article{480bfa5ed2a5464294c859d136cf9465,
title = "Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis",
abstract = "Background Paraoxonase 1 (PON1) is a serum high-density lipoprotein-bound enzyme with antioxidant function. It hydrolyses lipid peroxides, protecting low-density lipoproteins from oxidative modifications. Patients with psoriasis are at greater risk of oxidative stress, which is associated with abnormal plasma lipid metabolism. Objectives In this study, association of the PON1 55 M allele with serum arylesterase (ARE) activity, malondialdehyde (MDA), lipid profiles and psoriasis was investigated. Methods The present case-control study consisted of 100 patients with psoriasis with and without cardiovascular diseases (mean age 35·3 years) and 100 sex- and age-matched unrelated healthy controls (mean age 35·7 years) from the population of western Iran. The PON1 55 Met>Leu polymorphism was detected by polymerase chain reaction-restriction fragment length polymorphism. Serum ARE activity, MDA, and lipid and apolipoprotein levels were determined spectrophotometrically, by high-performance liquid chromatography and by enzyme assay, respectively. Results The presence of the PON1 55 M allele was found to be associated with psoriasis (odds ratio = 1·96, P = 0·017). The patients with psoriasis with the PON1 M (M/L + M/M) allele had higher MDA levels (4·12 ± 0·88 vs. 2·24 ± 0·55 μmol L -1, P < 0·001), apolipoprotein B (APOB)/APOA1 ratio (0·91 ± 0·66 vs. 0·66 ± 0·35, P = 0·004), APOB (111 ± 38·7 vs. 88·3 ± 22·5 mg mL-1, P = 0·001) and lipoprotein(a) [LP(a)] (21·9 ± 18·4 vs. 15·8 ± 16·6 mg mL-1, P = 0·034), but lower ARE activity (39·6 ± 11 vs. 45·9 ± 11·8 U mL-1, P = 0·031) than the control subjects. ARE activity showed a significant positive correlation with APOA1 and a negative correlation with MDA concentration in patients with psoriasis. Conclusions The PON1 55 M allele is a risk factor for psoriasis. Carriers of this allele have high levels of MDA, APOB and LP(a), a high APOB/APOA1 ratio and low ARE activity. These results indicate that oxidative stress, impairment of the antioxidant system and abnormal lipid metabolism may play a role in the pathogenesis and progression of psoriasis and its related complications. These data suggest that patients with psoriasis are more susceptible to vascular diseases.",
author = "M. Asefi and A. Vaisi-Raygani and F. Bahrehmand and A. Kiani and Z. Rahimi and H. Nomani and A. Ebrahimi and H. Tavilani and Tayebeh Pourmotabbed",
year = "2012",
month = "12",
day = "1",
doi = "10.1111/j.1365-2133.2012.11170.x",
language = "English (US)",
volume = "167",
pages = "1279--1286",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis

AU - Asefi, M.

AU - Vaisi-Raygani, A.

AU - Bahrehmand, F.

AU - Kiani, A.

AU - Rahimi, Z.

AU - Nomani, H.

AU - Ebrahimi, A.

AU - Tavilani, H.

AU - Pourmotabbed, Tayebeh

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Background Paraoxonase 1 (PON1) is a serum high-density lipoprotein-bound enzyme with antioxidant function. It hydrolyses lipid peroxides, protecting low-density lipoproteins from oxidative modifications. Patients with psoriasis are at greater risk of oxidative stress, which is associated with abnormal plasma lipid metabolism. Objectives In this study, association of the PON1 55 M allele with serum arylesterase (ARE) activity, malondialdehyde (MDA), lipid profiles and psoriasis was investigated. Methods The present case-control study consisted of 100 patients with psoriasis with and without cardiovascular diseases (mean age 35·3 years) and 100 sex- and age-matched unrelated healthy controls (mean age 35·7 years) from the population of western Iran. The PON1 55 Met>Leu polymorphism was detected by polymerase chain reaction-restriction fragment length polymorphism. Serum ARE activity, MDA, and lipid and apolipoprotein levels were determined spectrophotometrically, by high-performance liquid chromatography and by enzyme assay, respectively. Results The presence of the PON1 55 M allele was found to be associated with psoriasis (odds ratio = 1·96, P = 0·017). The patients with psoriasis with the PON1 M (M/L + M/M) allele had higher MDA levels (4·12 ± 0·88 vs. 2·24 ± 0·55 μmol L -1, P < 0·001), apolipoprotein B (APOB)/APOA1 ratio (0·91 ± 0·66 vs. 0·66 ± 0·35, P = 0·004), APOB (111 ± 38·7 vs. 88·3 ± 22·5 mg mL-1, P = 0·001) and lipoprotein(a) [LP(a)] (21·9 ± 18·4 vs. 15·8 ± 16·6 mg mL-1, P = 0·034), but lower ARE activity (39·6 ± 11 vs. 45·9 ± 11·8 U mL-1, P = 0·031) than the control subjects. ARE activity showed a significant positive correlation with APOA1 and a negative correlation with MDA concentration in patients with psoriasis. Conclusions The PON1 55 M allele is a risk factor for psoriasis. Carriers of this allele have high levels of MDA, APOB and LP(a), a high APOB/APOA1 ratio and low ARE activity. These results indicate that oxidative stress, impairment of the antioxidant system and abnormal lipid metabolism may play a role in the pathogenesis and progression of psoriasis and its related complications. These data suggest that patients with psoriasis are more susceptible to vascular diseases.

AB - Background Paraoxonase 1 (PON1) is a serum high-density lipoprotein-bound enzyme with antioxidant function. It hydrolyses lipid peroxides, protecting low-density lipoproteins from oxidative modifications. Patients with psoriasis are at greater risk of oxidative stress, which is associated with abnormal plasma lipid metabolism. Objectives In this study, association of the PON1 55 M allele with serum arylesterase (ARE) activity, malondialdehyde (MDA), lipid profiles and psoriasis was investigated. Methods The present case-control study consisted of 100 patients with psoriasis with and without cardiovascular diseases (mean age 35·3 years) and 100 sex- and age-matched unrelated healthy controls (mean age 35·7 years) from the population of western Iran. The PON1 55 Met>Leu polymorphism was detected by polymerase chain reaction-restriction fragment length polymorphism. Serum ARE activity, MDA, and lipid and apolipoprotein levels were determined spectrophotometrically, by high-performance liquid chromatography and by enzyme assay, respectively. Results The presence of the PON1 55 M allele was found to be associated with psoriasis (odds ratio = 1·96, P = 0·017). The patients with psoriasis with the PON1 M (M/L + M/M) allele had higher MDA levels (4·12 ± 0·88 vs. 2·24 ± 0·55 μmol L -1, P < 0·001), apolipoprotein B (APOB)/APOA1 ratio (0·91 ± 0·66 vs. 0·66 ± 0·35, P = 0·004), APOB (111 ± 38·7 vs. 88·3 ± 22·5 mg mL-1, P = 0·001) and lipoprotein(a) [LP(a)] (21·9 ± 18·4 vs. 15·8 ± 16·6 mg mL-1, P = 0·034), but lower ARE activity (39·6 ± 11 vs. 45·9 ± 11·8 U mL-1, P = 0·031) than the control subjects. ARE activity showed a significant positive correlation with APOA1 and a negative correlation with MDA concentration in patients with psoriasis. Conclusions The PON1 55 M allele is a risk factor for psoriasis. Carriers of this allele have high levels of MDA, APOB and LP(a), a high APOB/APOA1 ratio and low ARE activity. These results indicate that oxidative stress, impairment of the antioxidant system and abnormal lipid metabolism may play a role in the pathogenesis and progression of psoriasis and its related complications. These data suggest that patients with psoriasis are more susceptible to vascular diseases.

UR - http://www.scopus.com/inward/record.url?scp=84870179338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870179338&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2133.2012.11170.x

DO - 10.1111/j.1365-2133.2012.11170.x

M3 - Article

VL - 167

SP - 1279

EP - 1286

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 6

ER -